BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26295173)

  • 1. Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists.
    Inoue K; Urushibara K; Kanai M; Yura K; Fujii S; Ishigami-Yuasa M; Hashimoto Y; Mori S; Kawachi E; Matsumura M; Hirano T; Kagechika H; Tanatani A
    Eur J Med Chem; 2015 Sep; 102():310-9. PubMed ID: 26295173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
    Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
    Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis and Evaluation of Novel Substituted (5-methyl-1H-pyrazol-3-yl)- 1,3,4-oxadiazole as Potent Androgen Receptor Antagonist.
    Andavar S; Vaithilingam M; Selvaraj D; Kumaran AA; Devanathan K
    Anticancer Agents Med Chem; 2020; 20(1):84-93. PubMed ID: 31755396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
    Lao K; Sun J; Wang C; Wang Y; You Q; Xiao H; Xiang H
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4212-4217. PubMed ID: 28757062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.
    Fousteris MA; Schubert U; Roell D; Roediger J; Bailis N; Nikolaropoulos SS; Baniahmad A; Giannis A
    Bioorg Med Chem; 2010 Oct; 18(19):6960-9. PubMed ID: 20826091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety.
    Chen H; Zhang J; Hu P; Qian Y; Li J; Shen J
    Bioorg Med Chem; 2019 Oct; 27(20):115081. PubMed ID: 31493989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
    Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
    Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
    Chen H; Yu YZ; Tian XM; Wang CL; Qian YN; Deng ZA; Zhang JX; Lv DJ; Zhang HB; Shen JL; Yuan M; Zhao SC
    Bioorg Med Chem; 2019 Jan; 27(1):133-143. PubMed ID: 30482547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.
    Saito Y; Mizokami A; Tsurimoto H; Izumi K; Goto M; Nakagawa-Goto K
    Eur J Med Chem; 2018 Sep; 157():1143-1152. PubMed ID: 30189396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.
    Guerrini A; Tesei A; Ferroni C; Paganelli G; Zamagni A; Carloni S; Di Donato M; Castoria G; Leonetti C; Porru M; De Cesare M; Zaffaroni N; Beretta GL; Del Rio A; Varchi G
    J Med Chem; 2014 Sep; 57(17):7263-79. PubMed ID: 25121586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel selective agents for the degradation of AR/AR-V7 to treat advanced prostate cancer.
    Yang Y; Lv G; Xiu R; Yang H; Wang W; Yu P; Zhang J; Ye L; Wang H; Tian J
    Eur J Med Chem; 2024 May; 271():116400. PubMed ID: 38626524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
    Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y
    Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.
    Wang A; Wang Y; Meng X; Yang Y
    Bioorg Med Chem; 2021 Feb; 31():115953. PubMed ID: 33388655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of novel androgen receptor antagonists via molecular modeling.
    Zhao C; Choi YH; Khadka DB; Jin Y; Lee KY; Cho WJ
    Bioorg Med Chem; 2016 Feb; 24(4):789-801. PubMed ID: 26780832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists.
    Yamamoto S; Matsunaga N; Hitaka T; Yamada M; Hara T; Miyazaki J; Santou T; Kusaka M; Yamaoka M; Kanzaki N; Furuya S; Tasaka A; Hamamura K; Ito M
    Bioorg Med Chem; 2012 Jan; 20(1):422-34. PubMed ID: 22094279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
    Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
    Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based virtual screening and identification of a novel androgen receptor antagonist.
    Song CH; Yang SH; Park E; Cho SH; Gong EY; Khadka DB; Cho WJ; Lee K
    J Biol Chem; 2012 Aug; 287(36):30769-80. PubMed ID: 22798067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
    Yu J; Zhou P; Hu M; Yang L; Yan G; Xu R; Deng Y; Li X; Chen Y
    Eur J Med Chem; 2019 Nov; 182():111608. PubMed ID: 31437779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.
    Kandil S; Westwell AD; McGuigan C
    Bioorg Med Chem Lett; 2016 Apr; 26(8):2000-4. PubMed ID: 26965862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
    He Y; Hwang DJ; Ponnusamy S; Thiyagarajan T; Mohler ML; Narayanan R; Miller DD
    J Med Chem; 2021 Aug; 64(15):11045-11062. PubMed ID: 34269581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.